Merck & Co Inc: (NYSE: MRK)

(U.S: NYSE) As of Apr 21 04:01 PM ET

 Add to portfolio

$56.47 USD

+0.21 (0.37%)

Volume: 11,263,810

Zacks Rank : 3-Hold [?]     #3    

Brokerage Reports

Search for reports:

0 items in cart

MERCK & CO INC [MRK]

Reports for Purchase

Showing records 1 - 20 ( 53 total )

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 1

03/20/2014

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 2

02/05/2014

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 3

12/31/2013

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 4

10/29/2013

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 5

09/12/2013

Company Report

Pages: 12

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 6

07/31/2013

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 7

06/20/2013

Company Report

Pages: 12

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 8

05/02/2013

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 9

03/21/2013

Company Report

Pages: 12

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 10

02/04/2013

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 11

02/01/2013

Company Report

Pages: 7

Fourth Quarter Revenue Impacted by a Full Quarter of Generic Competition for Singulair

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 12

12/13/2012

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 13

10/29/2012

Company Report

Pages: 6

Third Quarter Reflected the Singulair Patent Expiration

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 14

10/29/2012

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 15

09/06/2012

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 16

07/30/2012

Company Report

Pages: 6

Double-Digit 2Q EPS Growth Beat Expectations

Provider: J.J.B. Hilliard, W.L. Lyons

Analyst: O'NEIL S

Price: 25.00

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 17

07/30/2012

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 18

06/22/2012

Company Report

Pages: 22

Griffin Securities Updates Coverage on Ligand Pharma. (LGND)

Provider: GRIFFIN SECURITIES, INC.

Analyst: MARKEY K

Price: 75.00

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 19

06/08/2012

Company Report

Pages: 14

Price: 24.95

Research Provided by a Third Party

Company: MERCK & CO INC

Industry: LARGE CAP PHARMA

Record: 20

04/30/2012

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party